Expertise in
19
conditions

Dr. Richard D. Kim

Hematology Oncology | Hematology | Oncology
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
12902 Usf Magnolia Dr, 
Tampa, FL 
Accepting New Patients
Offers Telehealth
Expertise in
19
conditions
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
12902 Usf Magnolia Dr, 
Tampa, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Richard Kim is a Hematologist Oncology specialist and a Hematologist in Tampa, Florida. Dr. Kim is highly rated in 19 conditions, according to our data. His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Kim is currently accepting new patients.

His clinical research consists of co-authoring 152 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

H LEE MOFFITT CANCER CTR AND RES INST LIFE TIME CANCER SCRN CTR INC
12902 Usf Magnolia Dr, Tampa, FL 33612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

Early Supportive Care and Nutritional Support in Adults With Pancreatic Cancer
Early Supportive Care and Nutritional Support in Adults With Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Behavioral
Study Phase: Not Applicable
Phase I Study of Regorafenib and Nivolumab in Mismatch Repair (MMR) Proficient Advanced Refractory Colorectal Cancer
Phase I Study of Regorafenib and Nivolumab in Mismatch Repair (MMR) Proficient Advanced Refractory Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 14, 2025
Intervention Type: Drug
Study Drugs: Regorafenib, Nivolumab
Study Phase: Phase 1
MRI Guided Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma to Enhance Complete Response
MRI Guided Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma to Enhance Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Radiation, Drug
Study Drugs: Capecitabine, FOLFOX regimen
Study Phase: Early Phase 1
A Phase II Investigator Sponsored Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
A Phase II Investigator Sponsored Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: September 22, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Study of Regorafenib and Pembrolizumab in Metastatic Colorectal Cancer Patients in 3rd and 4th Line Setting
A Phase I/II Study of Regorafenib and Pembrolizumab in Metastatic Colorectal Cancer Patients in 3rd and 4th Line Setting
Enrollment Status: Active_not_recruiting
Publish Date: July 04, 2025
Intervention Type: Drug, Biological
Study Drugs: Pembrolizumab, Regorafenib
Study Phase: Phase 1/Phase 2
An Open-label Window of Opportunity Trial to Evaluate the Activity of Durvalumab (MEDI4736) and Tremelimumab With Platinum-based Chemotherapy (Gemcitabine and Cisplatin) in Intrahepatic Cholangiocarcinoma (ICC)
An Open-label Window of Opportunity Trial to Evaluate the Activity of Durvalumab (MEDI4736) and Tremelimumab With Platinum-based Chemotherapy (Gemcitabine and Cisplatin) in Intrahepatic Cholangiocarcinoma (ICC)
Enrollment Status: Terminated
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drug: Chemotherapy+Immunotherapy
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Study Phase: Phase 1
A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma
A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Cobimetinib
Study Phase: Phase 2
A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy
A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy
Enrollment Status: Completed
Publish Date: October 25, 2023
Intervention Type: Drug
Study Drug: M7824
Study Phase: Phase 2
An Investigator-initiated Phase I Study of SELINEXOR in Combination With Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
An Investigator-initiated Phase I Study of SELINEXOR in Combination With Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
Enrollment Status: Terminated
Publish Date: October 17, 2022
Intervention Type: Drug
Study Drugs: Selinexor, Bevacizumab, Atezolizumab
Study Phase: Phase 1
A Phase I/II Study of Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers
A Phase I/II Study of Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers
Enrollment Status: Completed
Publish Date: June 03, 2022
Intervention Type: Drug
Study Drugs: Pembrolizumab, Ibrutinib
Study Phase: Phase 1/Phase 2
Phase I Study of Pre-operative Capecitabine and Lenvatinib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma
Phase I Study of Pre-operative Capecitabine and Lenvatinib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma
Enrollment Status: Completed
Publish Date: May 31, 2022
Intervention Type: Drug, Radiation
Study Drugs: Lenvatinib, Capecitabine
Study Phase: Phase 1
A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 DART® Protein in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory Metastatic Colorectal Carcinoma
A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 DART® Protein in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory Metastatic Colorectal Carcinoma
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 DART® Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma
A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 DART® Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Drug
Study Phase: Phase 1
Multi Institutional Phase II Trial of Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Multi Institutional Phase II Trial of Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Enrollment Status: Completed
Publish Date: October 12, 2021
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Phase I Trial With Cohort Expansion of Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
A Phase I Trial With Cohort Expansion of Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Drug
Study Phase: Phase 1
Phase II Study of Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
Phase II Study of Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
Enrollment Status: Completed
Publish Date: August 04, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1a/1b Trial of Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
A Phase 1a/1b Trial of Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Drug
Study Drugs: Trametinib, Sorafenib
Study Phase: Phase 1
Phase II Trial of FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
Phase II Trial of FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
Enrollment Status: Terminated
Publish Date: November 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Enrollment Status: Completed
Publish Date: September 11, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Trial of Sorafenib and Bavituximab Plus Stereotactic Body Radiation Therapy (SBRT) for 1st Line Treatment of Unresectable Hepatocellular Carcinoma
A Phase I Trial of Sorafenib and Bavituximab Plus Stereotactic Body Radiation Therapy (SBRT) for 1st Line Treatment of Unresectable Hepatocellular Carcinoma
Enrollment Status: Withdrawn
Publish Date: June 05, 2020
Intervention Type: Radiation, Drug
Study Phase: Phase 1
View 20 Less Clinical Trials
Similar Doctors
Expertise in
36
conditions
Dr. Jeffrey Lancet
Hematology Oncology | Hematology | Oncology
Expertise in
36
conditions
Dr. Jeffrey Lancet
Hematology Oncology | Hematology | Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeffrey Lancet is a Hematologist Oncology specialist and a Hematologist in Tampa, Florida. Dr. Lancet is highly rated in 36 conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
13
conditions
Dr. Tawee Tanvetyanon
Hematology Oncology | Hematology | Oncology
Expertise in
13
conditions
Dr. Tawee Tanvetyanon
Hematology Oncology | Hematology | Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tawee Tanvetyanon is a Hematologist Oncology specialist and a Hematologist in Tampa, Florida. Dr. Tanvetyanon is highly rated in 13 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Small Cell Lung Cancer (SCLC), and Thymectomy. Dr. Tanvetyanon is currently accepting new patients.

Expertise in
20
conditions
Dr. Rachid C. Baz
Hematology Oncology | Hematology | Oncology
Expertise in
20
conditions
Dr. Rachid C. Baz
Hematology Oncology | Hematology | Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

2590 Healing Way, 200 Moffitt Wesley Chapel, 
Wesley Chapel, FL 
 (10.0 miles away)
813-745-4673
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rachid Baz is a Hematologist Oncology specialist and a Hematologist in Wesley Chapel, Florida. Dr. Baz is highly rated in 20 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Plasmacytoma, Relapsed Refractory Multiple Myeloma (RRMM), Waldenstrom Macroglobulinemia, and Bone Marrow Aspiration. Dr. Baz is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kim's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile